Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie Sees Continued Positive Results for Leukemia Treatment

06/11/2021 | 05:20am EDT

By Chris Wack

AbbVie said it saw continued positive results from a four-year follow-up analysis of its Phase 3 CLL14 trial.

The pharmaceutical company said the trial showed that previously untreated patients with chronic lymphocytic leukemia with coexisting conditions who were treated with Venclyxto/Venclexta venetoclax plus obinutuzumab continued to show longer progression-free survival and higher rates of undetectable minimal residual disease compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil.

"The CLL14 trial results observed after four years of follow-up with treatment of venetoclax plus obinutuzumab show that these patients can experience long-lasting responses without disease progression, years after stopping treatment," said Mohamed Zaki, vice president and head of global oncology development at AbbVie.

After a median follow-up of more than four years, patients treated with the Venclyxto/Venclexta and obinutuzumab combination continued to demonstrate longer progression free survival compared to patients on treatment with obinutuzumab and chlorambucil, and the risk of disease progression or death was reduced by 67%.

No new safety signals were observed in the four-year follow-up analysis. The most frequently occurring serious adverse reactions in patients receiving venetoclax in combination with obinutuzumab were pneumonia, sepsis, febrile neutropenia, and TLS.

Venclyxto/Venclexta is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

06-11-21 0720ET

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. -0.71% 115.42 Delayed Quote.7.72%
DJ INDUSTRIAL 0.04% 34479.6 Delayed Quote.12.61%
ROCHE HOLDING AG 0.37% 342 Delayed Quote.10.68%
All news about ABBVIE INC.
06/11AbbVie Sees Continued Positive Results for Leukemia Treatment
DJ
06/11ABBVIE  : Says Follow-Up Analysis on Venetoclax Showed Sustained Progression-Fre..
MT
06/11ABBVIE  : New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combinati..
PR
06/11PRESS RELEASE : Roche announces data at EHA2021 -2-
DJ
06/09ABBVIE  : Allergan Aesthetics and BOTOX Cosmetic (onabotulinumtoxinA) Put Real S..
AQ
06/09ABBVIE  : Working With Caraway Therapeutics to Develop Small Molecule Therapeuti..
MT
06/08ABBVIE  : CAPTIVATE Study Shows an IMBRUVICA (ibrutinib) Plus VENCLEXTA/VENCLYXT..
AQ
06/08ABBVIE  : Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real ..
PR
06/07ABBVIE  : Reports Encouraging Data From Phase 2 Study of Imbruvica/Venclexta Com..
MT
06/07First New Alzheimer's Drug in Nearly Two Decades Is Approved by FDA -- 3rd Up..
DJ
More news
Financials (USD)
Sales 2021 55 834 M - -
Net income 2021 13 933 M - -
Net Debt 2021 66 251 M - -
P/E ratio 2021 14,7x
Yield 2021 4,41%
Capitalization 204 B 204 B -
EV / Sales 2021 4,84x
EV / Sales 2022 4,32x
Nbr of Employees 48 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 122,85 $
Last Close Price 115,42 $
Spread / Highest target 24,8%
Spread / Average Target 6,44%
Spread / Lowest Target -10,8%
EPS Revisions
Managers and Directors
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.7.72%203 857
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ELI LILLY AND COMPANY32.72%203 704